Definitions
Wiktionary
- n. A humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.
Etymologies
- epra- + -tu- + -zu- + -mab (Wiktionary)
Examples
“That trial, conducted on 227 lupus patients, sets the stage for the two companies to plan their third phase of human tests on the drug, called epratuzumab and still years away from potential approval.”
Jacksonville Business News - Local Jacksonville News | Jacksonville Business Journal
“The so-called treatment advantage of epratuzumab over placebo in was 25%.”
The Wall Street Journal: Immunomedics Lupus Treatment Shows Success
“Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.”
“The SN-38 conjugate of epratuzumab is one of several agents created by our ADC program.”
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance
“Studies in 4 B-cell lymphoma cell lines and 4 acute lymphoblastic leukemia cell lines confirmed the potent in vitro activity of epratuzumab-SN-38 in the nanomolar range.”
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance
“The potential therapeutic activity of epratuzumab-SN-38 is the combined effect of both the antibody and the drug.”
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance
“These results indicate that the epratuzumab-SN-38 conjugate is a potentially potent therapeutic, which can be significantly enhanced when combined with anti-CD20 immunotherapy, representing a new ADC treatment regimen.”
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance
“The Pharmacor 2010 findings also reveal that the entry and uptake of premium-priced biologics that include Benlysta, Biogen Idec/Roche/Genentech's ocrelizumab, and Immunomedics/UCB's epratuzumab will drive the overall systemic lupus erythematosus drug market to more than quadruple over the next decade.”
“UCB has announced they will initiate a Phase III program for epratuzumab in lupus during calendar year 2010”
Lists
‘epratuzumab’ hasn't been added to any lists yet.
Tweets
Looking for tweets for epratuzumab.
Comments
No comments yet...
Log in or sign up to get involved in the conversation. It's quick and easy.